Drugs / 68Ga-PSMA-0057
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT07310355 | Dec 2025 → Jun 2028 expected | castration-resistant prostate carcinoma | Chengdu StarRay Therapeutics Co., Ltd | Not yet recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 68Ga-PSMA-0057 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07310355 ↗ |
| Modality | Diagnostic / imaging agent | “imaging agent for PET/CT.” NCT07310355 ↗ |
| Route | Intravenous | “68Ga-PSMA-0057 IV administered” NCT07310355 ↗ |